Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naive TP53(WT) Merkel cell carcinoma (MCC)
Michael K. Wong,Melissa Burgess,Sunandana Chandra,Dirk Schadendorf,Ann Silk,Anthony J. Olszanski,Jean-Jacques Grob,Sekwon Jang,Jaspreet Singh Grewal,Karl D. Lewis,Leslie Fecher,Guilherme Rabinowits,Celeste Lebbe,Juan Martin-Liberal,Anna Maria Di Giacomo,Philip Friedlander,Andrew S. Brohl,Brandon Croft,Jesse S. McGreivy,Wayne P. Rothbaum,Glenn J. Hanna,Ciara M. Kelly JOURNAL OF INVESTIGATIVE DERMATOLOGY(2022)
AI 理解论文
溯源树
样例